查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1122328

黃斑變性治療市場：按類型、階段、管理途徑、分銷渠道、地區 - 規模、份額、前景和機會分析，2022-2028

Macular Degeneration Treatment Market, By Type, By Stage Of Disease, By Route Of Administration, By Sales Channel, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 174 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

黃斑變性是一種眼部疾病，會影響黃斑（眼睛後部視網膜的感光中心）並降低中心視力。它通常是由異常血管將液體或血液滲入黃斑引起的。年齡相關性黃斑變性有兩種類型：乾性和濕性。沒有治愈方法，但黃斑變性 (AMD) 治療可以減緩疾病的進展並防止嚴重的視力喪失。然而，治療取決於疾病的階段和類型。幹型往往比濕型進展得更慢，目前還沒有批准的治療方法或治療方法。幹型更常見，通常進展緩慢（多年）。然而，治療取決於 AMD 的類型。

市場動態。

視網膜疾病患病率的上升、老年人口的增加、對安全有效治療的需求上升、臨床試驗的增加等預計將成為推動全球黃斑變性治療市場增長的主要因素。例如，根據美國疾病控制和預防中心 (CDC) 的數據，年齡相關性黃斑變性是全球失明的主要原因，也是 65 歲及以上美國人視力喪失和失明的主要原因。到 2050 年，預計從 4800 萬增加到 8800 萬。

2021 年 9 月，美國食品藥品監督管理局 (Food and Drug Administration) (FDA) 宣布了首個用於新血管形成的 Lucentis（雷珠單抗注射液）生物仿製藥，這是導致 65 歲及以上美國人視力喪失和失明的主要原因。治療多種眼部疾病，包括老年性黃斑變性（nAMD）。

本研究的主要特點

  • 本報告對全球黃斑變性治療市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2028 年）的市場規模和復合年增長率 (CAGR %)。我是這裡。
  • 它還揭示了不同細分市場的潛在收入機會，並為該市場概述了一個有吸引力的投資建議矩陣。
  • 它還提供有關市場驅動因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭策略等方面的重要見解。
  • 它根據以下參數描述了全球黃斑變性治療市場的主要參與者，包括公司亮點、產品組合、關鍵亮點、績效和策略。
  • 本研究涵蓋的主要公司包括 Bayer AG、REGENXBIO Inc.、Panoptica、Pfizer Inc.、F. Hoffmann-La Roche Ltd.、Regeneron Pharmaceutical Inc.、Novartis AG、Aerie Pharmaceutical Inc. 和 Bausch健康公司
  • 本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。.
  • 全球黃斑變性治療市場報告迎合了該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
  • 利益相關者可以通過用於分析全球黃斑變性治療市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第二章市場展望

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 市場快照：按類型
    • 市場概況：按疾病階段
    • 按管理途徑劃分的市場概況
    • 市場快照：按銷售渠道
    • 市場概況：按地區劃分
  • 連貫的機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

  • 市場動態
    • 全球視網膜疾病負擔不斷上升
    • 對黃斑變性的認識不足
    • 對安全有效治療的需求不斷增加
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/批准
  • PEST 分析
  • PORTER 分析
  • 併購方案

第 4 章黃斑變性治療市場：冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 的流行病學
  • 供應方和需求方分析
  • 經濟影響

第 5 章黃斑變性治療市場：按類型，2017-2028 年

  • 乾性老年性黃斑變性
  • 濕性老年性黃斑變性

第 6 章黃斑變性治療市場：分階段，2017-2028

  • 早期 AMD
  • 中期 AMD
  • 晚期 AMD

第 7 章黃斑變性治療市場：按管理途徑，2017-2028 年

  • 靜脈給藥途徑
  • 玻璃體內給藥途徑

第 8 章黃斑變性治療市場：按分銷渠道，2017-2028

  • 門診手術中心
  • 醫院
  • 其他銷售渠道

第 9 章黃斑變性治療市場：2017-2028 年各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
  • 世界其他地區

第 10 章競爭格局

  • Bayer AG, REGENXBIO Inc.
  • Aerie Pharmaceutical Inc.
  • Panoptica
  • Pfizer Inc.
  • Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceutical Inc.
  • Novartis AG
  • Bausch Health Companies Inc.

第 11 章章節

  • 調查方法介紹
  • 關於出版商
簡介目錄
Product Code: CMI5149

Macular Degeneration is an eye disease affecting the macula (the centre of the light-sensitive retina at the back of the eye), causing loss of central vision. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula. There are 2 types of age-related macular degeneration, such as dry and wet. There is no cure, but macular degeneration (AMD) treatment help slow the disease and keep people from having a severe vision loss. However, the treatment depends on the stage and type. Dry AMD tends to progress more slowly than the wet type, and there is not, as of yet, an approved treatment or cure. The dry type is more common, but it usually progresses slowly (over years). However, treatment depends on the type of AMD.

Market Dynamics:

Increasing prevalence of retinal disease, growing geriatric population, rise in demand for safe and effective treatment, and increasing number of clinical trials are major factors expected to propel growth of the global macular degeneration treatment market. For instance, according to the Centers for Disease Control and Prevention (CDC), age-related macular degeneration is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans aged 65 years and older, and the number of older Americans is projected to nearly double from 48 million to 88 million in 2050.

In September 2021, the United States Food and Drug Administration (FDA) approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye conditions, including neovascular age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.

Key features of the study:

  • This report provides in-depth analysis of the global macular degeneration treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global macular degeneration treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Bayer AG, REGENXBIO Inc., Panoptica, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Aerie Pharmaceutical Inc., and Bausch Health Companies Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global macular degeneration treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global macular degeneration treatment market.

Detailed Segmentation:

  • Global Macular Degeneration Treatment Market, By Type:
    • Dry Age-related Macular Degeneration
    • Wet Age-related Macular Degeneration
  • Global Macular Degeneration Treatment Market, By Stage of Disease:
    • Early-stage AMD
    • Intermediate AMD
    • Late-stage AMD
  • Global Macular Degeneration Treatment Market, By Route of Administration:
    • Intravenous Route
    • Intravitreal Route
  • Global Macular Degeneration Treatment Market, By Sales Channel:
    • Ambulatory Surgical Centres
    • Hospitals
    • Other Sales Channels
  • Global Macular Degeneration Treatment Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • South America
    • Middle East & Africa

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type
    • Market Snapshot, By Stage od Disease
    • Market Snapshot, By By Route of Administration
    • Market Snapshot, By Sales Channel
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing burden of retinal disorders worldwide
    • Lack of awareness regarding macular degeneration
    • Increasing demand for safe and effective treatment
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Macular Degeneration Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Macular Degeneration Treatment Market, By Type, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Dry Age-related Macular Degeneration
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Wet Age-related Macular Degeneration
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Macular Degeneration Treatment Market, By Stage of Disease, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Early-stage AMD
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Intermediate AMD
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Late-stage AMD
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Macular Degeneration Treatment Market, By Route of Administration, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Intravenous Route
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Intravitreal Route
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

8. Macular Degeneration Treatment Market, By Sales Channel, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Ambulatory Surgical Centres
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Sales Channels
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

9. Macular Degeneration Treatment Market, By Geography, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

10. Competitive Landscape

  • Bayer AG, REGENXBIO Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Aerie Pharmaceutical Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Panoptica
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hoffmann-La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Regeneron Pharmaceutical Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bausch Health Companies Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us